Hostname: page-component-848d4c4894-x24gv Total loading time: 0 Render date: 2024-05-20T13:37:40.340Z Has data issue: false hasContentIssue false
  • English
  • Français

Visual Defects Associated with Vigabatrin: A Study of Epileptic Argentine Patients

Published online by Cambridge University Press:  02 December 2014

María Cecilia Moreno ,
Brenda Giagante ,
Patricia Saidon ,
Silvia Kochen ,
Jorge Benozzi  and
Ruth E. Rosenstein
María Cecilia Moreno
Affiliation:
Laboratory of Retinal Neurochemistry, Epilepsy Center, “Ramos Mejía” Hospital, School of Medicine, University of Buenos Aires, Paraguay, 2155, 5º P, (1121), Buenos Aires, Argentina
Brenda Giagante
Affiliation:
Laboratory of Experimental Ophthalmology, Department of Human Biochemistry, Epilepsy Center, “Ramos Mejía” Hospital, School of Medicine, University of Buenos Aires, Paraguay, 2155, 5º P, (1121), Buenos Aires, Argentina
Patricia Saidon
Affiliation:
Laboratory of Experimental Ophthalmology, Department of Human Biochemistry, Epilepsy Center, “Ramos Mejía” Hospital, School of Medicine, University of Buenos Aires, Paraguay, 2155, 5º P, (1121), Buenos Aires, Argentina
Silvia Kochen
Affiliation:
Laboratory of Experimental Ophthalmology, Department of Human Biochemistry, Epilepsy Center, “Ramos Mejía” Hospital, School of Medicine, University of Buenos Aires, Paraguay, 2155, 5º P, (1121), Buenos Aires, Argentina
Jorge Benozzi
Affiliation:
Laboratory of Retinal Neurochemistry, Epilepsy Center, “Ramos Mejía” Hospital, School of Medicine, University of Buenos Aires, Paraguay, 2155, 5º P, (1121), Buenos Aires, Argentina
Ruth E. Rosenstein*
Affiliation:
Laboratory of Retinal Neurochemistry, Epilepsy Center, “Ramos Mejía” Hospital, School of Medicine, University of Buenos Aires, Paraguay, 2155, 5º P, (1121), Buenos Aires, Argentina
*
Departamento de Bioquímica Humana, Facultad de Medicina, UBA, Paraguay 2155, 5º P, (1121), Buenos Aires, Argentina
Rights & Permissions [Opens in a new window]

Abstract:

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Objective:

The aim of the present study was to assess visual alterations in a population of Argentine patients treated with the antiepileptic drug vigabatrin.

Methods:

Twenty patients receiving vigabatrin and 15 patients receiving carbamazepine were examined with automated perimetry using a Humphrey 120-point full screening strategy. In addition, scotopic flash electroretinograms were performed.

Results:

Of 20 patients treated with vigabatrin, two were unable to cooperate with testing. Of the remaining 18 patients, all but two showed at least one non-detected point inside the central 40° of the visual field of each eye. Of the 15 carbamazepine-treated patients, three were unable to perform the study. None of the remaining 12 patients showed visual field defects. Both a- and b-wave amplitudes of the scotopic electroretinogram were significantly reduced in 12 patients receiving vigabatrin.

Conclusions:

Visual field defects among patients on vigabatrin therapy may occur with a higher frequency than previously recognized. The Humphrey 120-points full field screening test and electroretinography are useful tools to assess the visual dysfunction associated with vigabatrin.

Résumé:

RÉSUMÉ:Objectif:

Le but de cette étude était d’évaluer les changements visuels chez un groupe de patients argentins traités par le vigabatrin, un médicament anti-épileptique.

Méthodes:

Vingt patients recevant du vigabatrin et 15 patients recevant de la carbamazépine ont subi une périmétrie de dépistage plein écran de 120 points au moyen de l’appareil automatisé Humphrey. De plus, des électrorétinogrammes au flash scotopique ont été effectués.

Résultats:

L’étude n’a pu être réalisée chez deux des 20 patients traités par le vigabatrin à cause de leur manque de coopération. Chez les 18 autres patients, tous sauf deux avaient au moins un point non détecté au champ visuel central de 40o de chaque oeil. Trois des 15 patients recevant de la carbamazépine n’ont pu compléter l’étude. Aucun des 12 autres patients n’avait de déficit au niveau des champs visuels. L’amplitude des ondes a et b de l’électrorétinogramme scotopique était significativement diminuée chez 12 patients recevant le vigabatrin.

Conclusions:

Des anomalies du champ visuel sont peut-être plus fréquentes qu’on ne l’estimait chez les patients recevant du vigabatrin. La périmétrie automatisée Humphrey plein écran de 120 points et l’électrorétinographie sont des méthodes utiles pour évaluer la dysfonction visuelle associée au vigabatrin.

Type
Original Article
Information
Canadian Journal of Neurological Sciences , Volume 32 , Issue 4 , November 2005 , pp. 459 - 464
Copyright
Copyright © The Canadian Journal of Neurological 2005

References

1. Eke, T, Talbot, JF, Lawden, MC. Severe persistent visual fieldconstriction associated with vigabatrin. BMJ 1997; 314: 180–181.Google Scholar
2. Harding, GF, Robertson, KA, Edson, AS, et al. Visualelectrophysiological effect of a GABA transaminase blocker. Doc Ophthalmol 1998; 97: 179–188.CrossRefGoogle ScholarPubMed
3. Kalviainen, R, Nousiainen, I, Mantyjarvi, , et al. Vigabatrin, aGABAergic antiepileptic drug, causes concentric visual field defects. Neurology 1999; 53: 922–926.CrossRefGoogle Scholar
4. Toggweiler, S, Wieser, HG. Concentric visual field restriction undervigabatrin therapy: extent depends on the duration of drug intake. Seizure 2001; 10: 420–423.Google Scholar
5. Mauri-Llerda, JA, Iniguez, C, Tejero-Juste, C, et al. Visual fieldchanges secondary to vigabatrin treatment. Rev Neurol 2000; 31: 1104–1108.Google Scholar
6. Martinez, C, Noack, H. The risk of visual field defects and the use ofvigabatrin. Denham: Hoechst Marion Roussel, 1997. (Internal report.)Google Scholar
7. Lawden, MC, Eke, T, Degg, C, et al. Visual field defects associatedwith vigabatrin therapy. J Neurol Neurosurg Psychiatry 1999; 67: 716–722.CrossRefGoogle Scholar
8. Miller, NR, Johnson, MA, Paul, SR, et al. Visual dysfunction inpatients receiving vigabatrin: clinical and electrophysiologicfindings. Neurology 1999; 53: 2082–2087.Google Scholar
9. Midelfart, A, Midelfart, E, Brodtkorb, E. Visual field defects inpatients taking vigabatrin. Acta Ophthalmol Scand 2000; 78: 580–584.CrossRefGoogle Scholar
10. Krauss, GL, Johnson, MA, Miller, NR. Vigabatrin-associated retinalcone system dysfunction: electroretinogram and ophthalmologicfindings. Neurology 1998; 50: 614–618.Google Scholar
11. Harding, GF, Wild, JM, Robertson, KA, et al. Separating the retinalelectrophysiologic effects of vigabatrin: treatment versus fieldloss. Neurology 2000; 55: 347–352.Google Scholar
12. Johnson, MA, Krauss, GL, Miller, NR, et al. Visual function loss fromvigabatrin: effect of stopping the drug. Neurology 2000; 55: 40–45.Google Scholar
13. Daneshvar, H, Racette, L, Coupland, SG, et al. Symptomatic andasymptomaticvisual lossinpatientstaking vigabatrin. Ophthalmology 1999; 106: 1792–1798.Google Scholar
14. Comaish, IF, Gorman, C, Brimlow, GM, et al. The effects ofvigabatrin on electrophysiology and visual fields in epileptics: a controlled study with a discussion of possible mechanisms. Doc Ophthalmol. 2002; 104: 195–212.Google Scholar
15. Mosinger, JL, Yazulla, S, Studholme, KM. GABA-likeimmunoreactivity in the vertebrate retina: a species comparison. Exp Eye Res 1986; 42: 631–644.Google Scholar
16. Lopez-Costa, JJ, Goldstein, J, Pecci-Saavedra, J, et al. GABA releasemechanism in the golden hamster retina. Int J Neurosci 1999; 98: 13–25.Google Scholar
17. Frumkes, TE, Nelson, R. Functional role of GABA in cat retina: I. Effects of GABAA agonists Vis Neurosci 1995; 12: 641–650.Google Scholar
18. Butler, WH, Ford, GP, Newberne, JW. A study of the effects ofvigabatrin on the central nervous system and retina of Sprague Dawley and Lister-Hooded rats. Toxicol Pathol 1987; 15: 143–148.Google Scholar
19. Gottlob, I, Wundsch, L, Tuppy, FK. The rabbit electroretinogram:effect of GABA and its antagonists. Vision Res 1988; 28: 203–210.Google Scholar
20. Sills, GJ, Patsalos, PN, Butler, E, et al. Visual field constriction:Accumulation of vigabatrin but not tiagabine in the retina. Neurology 2001; 57: 196–200.CrossRefGoogle Scholar
21. Neal, MJ, Shah, MA. Development of tolerance to the effects ofvigabatrin (gamma-vinyl-GABA) on GABA release from rat cerebral cortex, spinal cord and retina. Br J Pharmacol 1990; 100: 324–328.Google Scholar
22. Coupland, SG, Zackon, DH, Leonard, BC, Ross, TM. Vigabatrin effecton inner retinal function. Ophthalmology 2001; 108: 1493–1496.CrossRefGoogle Scholar